Alector at Cantor healthcare conference: brain-shuttle pipeline in focus

On Thursday, September 10, 2026, Alector (ALEC) addressed the 12th Annual Cantor Fitzgerald Global Healthcare Conference, emphasizing its focus on neurodegeneration. The company's brain-carrier platform and a lead Alzheimer's candidate, AL137, are at the forefront of its pipeline. Alector aims to enhance brain delivery and reduce safety problems associated with early-stage drug development.

The company's shares were trading at $2.07, down 8.81% from the previous close of $2.27, with a market capitalization of $231 million. InvestingPro analysis suggests the stock is undervalued at its current level, placing Alector on the list of the platform's most undervalued stocks. Alector's proprietary brain-carrier platform is designed to move drugs across the blood-brain barrier, minimizing anemia and off-target effects.

Their lead program, AL137, an anti-amyloid-beta antibody, is set to enter Phase I testing in April, starting with healthy volunteers in Australia and later in Alzheimer's patients in the U.S. Preclinical data indicates several-fold better brain exposure compared to competitor platforms, with no significant drop in red blood cells or hemoglobin in non-human primates.

Alector is exploring tau, alpha-synuclein, and GCase programs and is actively seeking partnerships for Parkinson's disease assets by the end of the year.